TO THE EDITOR
Therapy-related acute myeloid leukemia (tAML) has been well described following use of chemotherapeutic agents for treatment of malignant and less often nonmalignant diseases. [1] [2] [3] Treatment of multiple sclerosis (MS), an autoimmune central nervous system disease with a variable clinical course, most often with a gradual decline in neurologic function, has included the use of chemotherapeutic agents, such as methotrexate and mitoxantrone. 4 In recent years, rare reports have indicated the occurrence of acute myeloid leukemia (AML) in association with mitoxantrone use in the treatment of MS. 5 Acute promyelocytic leukemia (APL), a subtype of AML with characteristic morphologic, clinical, cytogenetic and molecular features, occurring after chemotherapy for neoplastic indications has also been documented.
1 However, only a few cases of therapy-related acute promyelocytic leukemia (tAPL) following the treatment of MS have been reported. 1, 6, 7 We report a case of a patient with MS treated with mitoxantrone, who developed APL 11 months after completion of therapy. . 8 Her hospital course was complicated with severe mucositis and Pseudomonas septicemia. Hematologic recovery was noted on day #36. Repeat bone marrow exam on day #38 showed normal trilineage hematopoiesis without evidence of residual leukemic cells. Cytogenetic analysis did not demonstrate chromosomal abnormalities. However, molecular testing by FISH revealed PML/RAR-alpha positivity in 4.5% cells. The patient subsequently underwent two consolidation treatments with daunorubicin (55 mg/m 2 ). A repeat bone marrow exam, on day #110, after completion of consolidation treatment, confirmed complete morphologic, cytogenetic and molecular remission.
Although tAML is well established and described, tAPL remains a rare occurrence, mostly described after therapy for malignant diseases. Most of the cases were described following the use of multiple agents, and the onset of APL was usually preceded by documented myelodysplastic features. 2, 3 In the recent past, increased use of topoisomerase II inhibitors has led to better documentation of their leukemogenic potential. Mitoxantrone, a topoisomerase II inhibitor, used in the treatment of various malignant diseases as well as MS, has been implicated in the development of tAML and tAPL.
1,5-7 A recent comprehensive review of tAPL, the largest in the literature to this date with 106 cases analyzed, implicated the use of at least one topo II inhibitor in 61 patients (57%), with mitoxantrone being the implicated agent in 28 cases (26%), but only two of them occurred in patients treated for nonmalignant condition.
1 Those numbers were consistent with previously published data. 3 Mitoxantrone has been used increasingly for the treatment of progressive MS, 4 but to the best of our knowledge only three cases have been reported so far regarding the development of APL in such a clinical scenario. 1, 6, 7 Our patient developed APL 11 months after completion of mitoxantrone therapy. Although the patient did receive one dose of intrathecal methotrexate, no occurrence of APL after a single intrathecal methotrexate has been documented to this date. Additionally, our patient was treated with b-IFN, which is not known to have a leukemogenic effect. Finally, the occurrence of de novo APL is certainly a possibility, but is arguably unlikely under the described set of circumstances and given the temporal relationship of the onset of APL to the implicated therapy. The incidence of APL following mitoxantrone therapy for MS is unknown, but appears to be extremely rare based on the available reports in the medical literature. 1, 6, 7 This case once again demonstrates the possible occurrence of APL following use of mitoxantrone in the treatment of MS. However, with the current therapeutic modalities, APL has become prognostically the most favorable subtype of AML and physicians should weigh these facts before deciding to use mitoxantrone in the treatment of MS.
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